Abstract
The article describes a clinical case of an increased level of hepatic transaminases during a delayed period of the treatment in a patient with coronavirus disease COVID-19 using remdesivir and a possible effect of hepatic steatosis on the severity of cytolytic syndrome associated with the course of COVID-19.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
